Home › Funds › Bracebridge Capital, LLC › AQST
Bracebridge Capital, LLC position in AQST
AQUESTIVE THERAPEUTICS INC COM · Health Care
Bracebridge Capital, LLC reported holding 459,216 shares of AQST (AQUESTIVE THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$1.9M, representing 0.48% of its reported portfolio and ranking #15 among its reported holdings. Bracebridge Capital, LLC has disclosed AQST holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bracebridge Capital, LLC's AQST position evolved
Bracebridge Capital, LLC first disclosed a stake in AQST in Q3 2023 at 428,571 shares (US$655.7M). The position peaked in Q1 2024 at 428,571 shares, worth US$1.83B. Across 12 filings, Bracebridge Capital, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 459,216 shares valued at US$1.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 428.57K | $655.71M | New |
| Q4 2023 | 428.57K | $865.71M | Hold |
| Q1 2024 | 428.57K | $1.83B | Hold |
| Q2 2024 | 428.57K | $1.11B | Hold |
| Q3 2024 | 428.57K | $2.13M | Hold |
| Q4 2024 | 459.22K | $1.63M | Add |
| Q1 2025 | 459.22K | $1.33M | Hold |
| Q2 2025 | 459.22K | $1.52M | Hold |
| Q3 2025 | 459.22K | $2.57M | Hold |
| Q4 2025 | 459.22K | $2.97M | Hold |
| Q1 2026 | 459.22K | $1.91M | Hold |
| Q2 2026 | 459.22K | $1.91M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AQST and 13F data
AQST (AQUESTIVE THERAPEUTICS INC COM) is a Health Care company. 40 other funds we track also report a position in AQST — the largest reported positions include Bratton Capital Management, L.P. (US$40.8M), Samsara BioCapital, LLC (US$10.4M), Sio Capital Management, LLC (US$6.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AQST
- Bratton Capital Management, L.P. 9.81M sh · $40.81M · Q2 2026
- Samsara BioCapital, LLC 2.50M sh · $10.40M · Q2 2026
- Sio Capital Management, LLC 1.49M sh · $6.18M · Q2 2026
- Propel Bio Management, LLC 1.44M sh · $6.00M · Q2 2026
- Blue Owl Capital Holdings LP 942.93K sh · $3.92M · Q2 2026
- DAFNA Capital Management LLC 645.91K sh · $2.69M · Q2 2026
- Everstar Asset Management, LLC 611.94K sh · $2.55M · Q2 2026
More on Bracebridge Capital, LLC
FAQ
How long has Bracebridge Capital, LLC held AQST?
Bracebridge Capital, LLC has disclosed AQST holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Bracebridge Capital, LLC's current position in AQST?
As of Q2 2026, Bracebridge Capital, LLC holds 459.22K shares of AQST (AQUESTIVE THERAPEUTICS INC COM), valued at $1.91M, representing 0.48% of its reported portfolio and ranking #15.
Has Bracebridge Capital, LLC been buying or selling AQST?
In the latest 13F filing (Q2 2026), Bracebridge Capital, LLC held unchanged its position in AQST. The position peaked in Q1 2024 at 428.57K shares.
Which other funds hold AQST?
Other major institutional holders of AQST include Bratton Capital Management, L.P., Samsara BioCapital, LLC, Sio Capital Management, LLC, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.